Half of the 45 million Americans with migraine require bedrest for relief. Migraine affects overall health, relationships, careers, and financial stability. Identifying, measuring, and targeting the full disease burden could improve patients' lives. Migraine medications are limited by side effects, lack of efficacy, and costs. Despite recommendations against opioid use due to risks of medication overuse headache and addiction, a third of Americans with migraine turn to opioids for acute relief. An unmet need exists for more effective migraine therapies that target headache-related impact with long-term efficacy, safety, and tolerability. Non-opioid, non-drug interventions are important for patients with migraine. Our prior research utilized designs with high methodological rigor (e.g., RCT) but were modest in size with only participants able to engage with in-person classes that limited generalizability. Such limitations may be offset by flexible online options. Patients with migraine are interested in electronic (e)Health options, yet few evidenced-based options exist. This proposal addresses these gaps with a large study using national recruitment and an online, accessible non-drug intervention that was developed for generalizable populations. We plan to test the efficacy of the intervention in adults with migraine in a phase 3 RCT. The main goal will be evaluation of efficacy (Aim 1), with secondary goals of understanding mechanisms (Aim 2) and gathering data (Aim 3) for a future, scalable implementation study. As done previously, the intervention will be matched with an attention-control group and participants will continue all current migraine medications, as we have shown medication plus behavioral treatments have the greatest relief on disease burden. This fully remotely delivered study will determine the efficacy of this non-drug intervention in adults with migraine to target the urgent need for better migraine treatments on the patient-centered outcome of headache-related impact. We are using an eHealth delivery format that increases availability compared to in-person weekly classes. If effective, this research will lead to an implementation trial so that ultimately, patients with migraine will have an easily accessible, standardized, non-drug, non-opioid treatment that could be used worldwide to target the highly prevalent disease of migraine and its associated headache-related impact.